Physiomics PLC Contract Award
2024年2月5日 - 4:00PM
RNS Non-Regulatory
RNS Number : 9131B
Physiomics PLC
05 February 2024
05 February 2024
Physiomics plc
("Physiomics" or the "Company")
Contract Award
Physiomics plc (AIM: PYC), a leading
mathematical modelling and data science company supporting the
development of new therapeutics and personalised medicine
solutions, is pleased to announce that it has been awarded a
further contract by existing client, Numab Therapeutics ("Numab").
The project involves Pharmacokinetic-Pharmacodynamic (PKPD)
modelling in support of one of Numab's oncology assets entering the
clinic and will help inform dose and scheduling
decisions.
Dr Peter
Sargent, CEO, commented: "We are thrilled to have this opportunity to
continue working with and supporting Numab on this asset through
its preclinical stages as it heads into the clinic. Along with the
project we announced with them in August 2023, this new project is
testament to the continued support we provide and the great
relationships we've built".
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines cutting edge
PKPD and QSP modelling and data science techniques, along with deep
biology expertise, to help biotech and pharma companies streamline
their drug development journeys.
Our approach is to derive insight
from all relevant data in order to de-risk decision making and
optimise design research across discovery, pre-clinical and
clinical studies.
Through use of bespoke models and
our proprietary Virtual Tumour technology, the Physiomics team has
informed the development of over 100 commercial projects, over 50
targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle
Therapeutics, Numab Therapeutics & CRUK.
This information is provided by Reach, the non-regulatory
press release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NRAUPUQGPUPCGCP
Physiomics (LSE:PYC)
過去 株価チャート
から 4 2024 まで 5 2024
Physiomics (LSE:PYC)
過去 株価チャート
から 5 2023 まで 5 2024